Nuvectis PharmaNVCT
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 41 institutions reported holding Nuvectis Pharma Inc. (NVCT) in their 13F filings, up 1 from Q1 2024. 16 opened new positions and 16 sold out. The largest holders were Vanguard Group Inc. ($1.6M), Baldwin Wealth Partners LLC ($1.1M) and Millennium Management ($756K). 3 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Nuvectis Pharma Inc.
- CUSIP
- 67080T108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 16 | $1.2M |
| Exits | 16 | $674K |
All 13F filers, Q1 2024 → Q2 2024: 337,889 shares bought and 698,033 shares sold, net −360,144 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 41 holders
| Vanguard Group Inc. | 0.00% | Reduce -15.9% | 251,138 | $1.6M |
| Baldwin Wealth Partners LLC | 0.08% | Add +9.4% | 168,630 | $1.1M |
| Millennium Management | 0.00% | Add +202.4% | 119,459 | $756K |
| BlackRock Inc. | 0.00% | Reduce -77.6% | 83,412 | $528K |
| Renaissance Technologies | 0.00% | Add +20.8% | 74,500 | $472K |
| Goldman Sachs Group Inc. | 0.00% | New | 61,570 | $390K |
| Geode Capital Management, LLC | 0.00% | Reduce -60.4% | 53,227 | $337K |
| Northern Trust Corp. | 0.00% | Reduce -19.8% | 49,827 | $315K |
| Gsa Capital Partners LLP | 0.02% | Add +23.1% | 48,339 | $306K |
| Forbes J M & Co. LLP | 0.03% | Add +39.5% | 47,419 | $300K |
| Marshall Wace, LLP | 0.00% | Reduce -32.4% | 33,868 | $214K |
| Y-Intercept (Hong Kong) Ltd | 0.01% | New | 23,173 | $147K |
| Edmond DE Rothschild Holding S.A. | 0.00% | No change | 19,170 | $121K |
| Jane Street Group, LLC | 0.00% | New | 17,021 | $108K |
| State Street Corp. | 0.00% | Reduce -88.2% | 15,300 | $97K |
| Citadel Advisors | 0.00% | New | 14,937 | $95K |
| JPMorgan Chase & Co. | 0.00% | Add +185.6% | 14,753 | $93K |
| HRT Financial LP | 0.00% | New | 13,627 | $86K |
| Centiva Capital, LP | 0.00% | New | 13,300 | $84K |
| Two Sigma Investments, LP | 0.00% | New | 13,044 | $83K |
| Baxter Bros Inc. | 0.01% | New | 12,500 | $79K |
| Morgan Stanley | 0.00% | Reduce -75.2% | 10,198 | $65K |
| Point72 Asia (Singapore) Pte. Ltd. | 0.01% | New | 9,203 | $58K |
| Barclays PLC | 0.00% | Reduce -19.6% | 8,270 | $52K |
| Qube Research & Technologies Ltd | 0.00% | New | 7,978 | $51K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +604.6% | 5,996 | $38K |
| Citigroup Inc. | 0.00% | Add +253.3% | 4,883 | $31K |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.00% | — | 3,254 | $21K |
| Rhumbline Advisers | 0.00% | Reduce -75.1% | 1,871 | $12K |
| Point72 (DIFC) Ltd | 0.00% | New | 1,249 | $8K |
| FMR LLC | 0.00% | Add +123.2% | 971 | $6K |
| Catalyst Funds Management Pty Ltd | 0.00% | New | 900 | $6K |
| Bank of America Corp. | 0.00% | Reduce -79.8% | 764 | $5K |
| Macquarie Group Ltd. | 0.00% | New | 355 | $2K |
| Hollencrest Capital Management | 0.00% | No change | 280 | $2K |
| Nisa Investment Advisors, LLC | 0.00% | New | 212 | $1K |
| Lanark Financial, Inc. | 0.00% | Add +200.0% | 300 | $1K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 100 | $633 |
| New York State Common Retirement Fund | 0.00% | Reduce -98.9% | 64 | $405 |
| UBS Group AG | 0.00% | Reduce -99.8% | 13 | $82 |
| Cwm, LLC | 0.00% | New | 16 | $0 |
"% of holder's portfolio" is NVCT's weight in each manager's 13F, not the share of Nuvectis Pharma Inc. the manager owns.